## **Voluntary Dose Management Programs**

The purpose of these dose management programs is to offer the prescriber a voluntary alternate dose that reduces drug waste without compromising the member's health.

## **Immunoglobulin Dose Adjustment Program**

The immunoglobulin dose adjustment program offers the prescriber an option to use adjusted body weight instead of the member's actual body weight to calculate the immune globulin dose when clinically appropriate.

This is a voluntary program and is not meant to replace clinical decision making by the prescriber. This information should only be used as a guide. Patient-specific variables should be considered. Declining to use adjusted body weight for dosing will not impact the precertification request.

Where clinically appropriate and with provider agreement, immune globulins may be dosed based on adjusted body weight (AdjBW) in individuals whose actual body weight (ABW) is 20% higher than his or her ideal body weight (IBW). The dosing formulas used to calculate adjusted body weight are:

- IBW (males) = 50 kg + (2.3 kg for each inch over 5 feet)
- IBW (females) = 45.5 kg + (2.3 kg for each inch over 5 feet)
- Adjusted body weight = IBW + 0.4 (actual body weight IBW)

Situations where dose adjustments may not apply to the member include:

- The individual is younger than 18 years of age
- The individual is less than 60 inches (5 feet) tall
- The dosing is based on a specific and measurable IgG level recommended for the indication requested
- The individual has been stable on current dose, and previous attempts to decrease or adjust the dose have resulted in worsening of symptoms or relapse
- Other patient-or indication-specific variables, or other factors per clinician's judgement

## List of drugs in scope

Asceniv	Gammaplex
Bivigam	Gamunex-C
Carimune NF	Hizentra
Cutaquig	Hyqvia
Cuvitru	Octagam 5%
Flebogamma DIF 5%	Octagam 10%
Flebogamma DIF 10%	Panzyga
Gammagard	Privigen
Gammagard S-D	Xembify
Gammaked	

## **Dose Vial Rounding Program**

The dose vial rounding program offers the prescriber an option to decrease the originally requested dose by up to 10% to the nearest whole vial size for specific oncology and non-oncology therapy in eligible members, where clinically appropriate.

This is a voluntary program and is not meant to replace clinical decision making by the prescriber. This information should only be used as a guide. Patient-specific variables should be considered. Declining to use the rounded down dose will not affect the final determination of the precertification request.

The number of vials used based on the requested dose will be compared to the number of vials needed for a 10% or less reduction in the dose. If a 10% or less reduction allows for a reduction in the number of vials needed, the option to decrease the original dose will be discussed with the provider.

Situations where dose adjustments may not apply to the member include:

- If there is a greater than 10% change to nearest whole vial, then the originally requested dose will be identified as the appropriate dose.
- The medication is supplied in a multiple-dose vial
- Other patient-or indication-specific variables, or other factors per clinician's judgement.

List of drugs in scope

List of drugs in sco	Oncology		Non-Oncology
Abraxane	Erwinaze	Oncaspar	Remicade
Actimmune	Ethyol	Ontruzant	Avsola
Adcetris	Folotyn	Opdivo	Renflexis
Alimta	Granix	Padcev	Inflectra
Amerinet	Halaven	Polivy	Ixifi
Asparlas	Herceptin	Poteligeo	
Avastin	Herzuma	Proleukin	
Beleodaq	Imfinzi	Riabni	
Bendeka	Infugem	Riabni	
Besponsa	Istodax	Rituxan	
Bicnu	Ixempra Kit	Ruxience	
Blenrep	Jevtana	Ruxience	
Blincyto	Kadcyla	Sarclisa	
Camptosar	Kanjinti	Sylvant	
Clolar	Keytruda	Trazimera	
Cosmegen	Kyprolis	Treanda	
Cyramza	Lumoxiti	Trisenox	
Dacogen	Margenza	Truxima	
Darzalex	Monjuvi	Vectibix	
Doxorubicin	Mutamycin	Velcade	
liposomal	Mvasi	Yervoy	
Eloxatin	Mylotarg	Yondelis	
Elzonris	Neupogen	Zaltrap	
Empliciti	Nipent	Zarxio	
Enhertu	Nivestym	Zepzelca	
Erbitux	Ogivri	Zirabev	